West Africa · Nigeria · Distribution intelligence

Pharma Distribution Intelligence — Nigeria

Distrolens maps NAFDAC-licensed pharma distributors across Nigeria — West Africa's largest pharmaceutical market. Brand portfolios, license currency, beneficial ownership signals from the CAC PSC register, and decision-maker contacts.

Coverage
NAFDAC import-licensed wholesalers + specialist agents
Registrations
Drug registrations refreshed weekly via NAFDAC GRP
Freshness
CAC PSC beneficial ownership signals + license events tracked

Market context

Why Nigeria matters

Nigeria is West Africa's largest pharmaceutical market — $1.8B+ and growing 13% annually. 150+ NAFDAC-licensed manufacturing facilities, hundreds of import-licensed wholesalers, anchored in Lagos, Onitsha, and Kano.

Primary regulator: National Agency for Food and Drug Administration and Control (NAFDAC)www.nafdac.gov.ng

What we map

Public-source signals for Nigeria

  • NAFDAC GRP product registrations and manufacturer of record
  • CAC PSC beneficial ownership (ground-truth ownership chains)
  • Lagos, Onitsha, Kano cluster geographies
  • ECOWAS re-export channels (Ghana, Côte d'Ivoire, Benin)
  • Federal and state-tier tender awards
  • Decision-maker contacts at top distributors

Use cases

How brand owners use Nigeria data

Brand owner entering Nigeria via licensed channel

We deliver a shortlist of NAFDAC import-licensed wholesalers whose portfolio fits your therapeutic class — with CAC PSC beneficial-ownership context to spot which entities are single-shareholder vs institutional.

Anti-counterfeit / parallel-trade scan

Authorized distributor mapping vs grey-market signals. Identify which channels carry your brand legitimately and which clusters surface anomalies.

Federal + state procurement intelligence

FMOH, FCDA, and high-volume state-level tender award patterns. Spot which distributors hold public-sector relationships in your therapeutic area.

Founder-led · Brief-form intake

Request a Nigeria brief

Send your therapeutic class, target launch window, and any constraints. We respond within 1 business day with scope, evidence sample, and timeline.

Start brief →
Other countries:UAESaudi ArabiaKenya